DE202019005887U1 - Anti-TCR-Antikörpermoleküle und Verwendungen davon - Google Patents

Anti-TCR-Antikörpermoleküle und Verwendungen davon Download PDF

Info

Publication number
DE202019005887U1
DE202019005887U1 DE202019005887.7U DE202019005887U DE202019005887U1 DE 202019005887 U1 DE202019005887 U1 DE 202019005887U1 DE 202019005887 U DE202019005887 U DE 202019005887U DE 202019005887 U1 DE202019005887 U1 DE 202019005887U1
Authority
DE
Germany
Prior art keywords
tcrβ
tcrβv
cell
molecule
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE202019005887.7U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marengo Therapeutics Inc
Original Assignee
Marengo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marengo Therapeutics Inc filed Critical Marengo Therapeutics Inc
Publication of DE202019005887U1 publication Critical patent/DE202019005887U1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE202019005887.7U 2018-07-03 2019-07-03 Anti-TCR-Antikörpermoleküle und Verwendungen davon Active DE202019005887U1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862693653P 2018-07-03 2018-07-03
US62/693,653 2018-07-03
US201862737829P 2018-09-27 2018-09-27
US62/737,829 2018-09-27
US201962788674P 2019-01-04 2019-01-04
US62/788,674 2019-01-04
US201962808700P 2019-02-21 2019-02-21
US62/808,700 2019-02-21

Publications (1)

Publication Number Publication Date
DE202019005887U1 true DE202019005887U1 (de) 2023-06-14

Family

ID=67441685

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202019005887.7U Active DE202019005887U1 (de) 2018-07-03 2019-07-03 Anti-TCR-Antikörpermoleküle und Verwendungen davon

Country Status (8)

Country Link
US (13) US11845797B2 (enExample)
EP (1) EP3818083A2 (enExample)
JP (2) JP7554742B2 (enExample)
CN (1) CN112955465A (enExample)
AU (1) AU2019297451A1 (enExample)
CA (1) CA3105448A1 (enExample)
DE (1) DE202019005887U1 (enExample)
WO (1) WO2020010250A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
MX386714B (es) 2015-01-27 2025-03-11 Lava Therapeutics N V Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用ＣＤ１ｄ免疫グロブリン
JP7700039B2 (ja) * 2019-01-04 2025-06-30 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
GB201901306D0 (en) * 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
WO2020172598A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
SG11202109122SA (en) * 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119954959A (zh) 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
CN115003698A (zh) * 2019-11-14 2022-09-02 马伦戈治疗公司 抗tcr抗体分子及其用途
GB201919061D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
EP4084821A4 (en) * 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
WO2021138474A2 (en) * 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2021155112A1 (en) * 2020-01-29 2021-08-05 The Trustees Of The University Of Pennsylvania Compositions and methods of t cell receptor vb family member targeting for the treatment of t cell associated disease
MX2022010034A (es) 2020-02-16 2022-12-13 Aulos Bioscience Inc Anticuerpos anti-il-2 diseñados.
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
CN111848797B (zh) * 2020-07-20 2021-02-09 北京鼎成肽源生物技术有限公司 一种靶向c-Met的单链抗体、嵌合抗原受体、重组载体、CAR-T细胞及应用
IL300505A (en) 2020-08-10 2023-04-01 Janssen Biotech Inc Materials and methods for the production of biologically engineered virus-specific lymphocytes
AU2021331075A1 (en) * 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
IL301242A (en) * 2020-09-11 2023-05-01 Janssen Biotech Inc Multi-specific immune targeting molecules and uses thereof
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
UY39415A (es) 2020-09-11 2022-03-31 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadenas beta
CN116867519A (zh) * 2020-12-01 2023-10-10 约翰斯霍普金斯大学 治疗t细胞癌症的方法和材料
CN113109564A (zh) * 2021-03-15 2021-07-13 成都益安博生物技术有限公司 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用
CA3214757A1 (en) * 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023081412A2 (en) * 2021-11-05 2023-05-11 Marengo Therapeutics, Inc. Immune cell populations and uses thereof
CN119233999A (zh) * 2022-05-25 2024-12-31 羿尊生物医药（浙江）有限公司 靶向细胞膜受体蛋白的融合蛋白及其应用
WO2023235772A2 (en) * 2022-05-31 2023-12-07 Fred Hutchinson Cancer Center Humanized anti-cd45 antibodies and uses thereof
EP4601619A4 (en) * 2022-10-12 2026-08-05 Marengo Therapeutics Inc MULTIFUNCTIONAL MOLECULES THAT BIND TO TCR AND THEIR USES
WO2024197296A1 (en) 2023-03-23 2024-09-26 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
WO2024254611A2 (en) * 2023-06-09 2024-12-12 Marengo Therapeutics, Inc. Multispecific molecules binding to tcr and uses thereof
WO2025049771A1 (en) * 2023-08-30 2025-03-06 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2025085862A2 (en) * 2023-10-20 2025-04-24 BioNTech SE Multispecific t cell engagers compositions and methods of use thereof
CN117442721B (zh) * 2023-12-20 2024-03-15 苏州艾凯利元生物科技有限公司 一种包括nk细胞和nk细胞接合器分子的组合物
WO2025222063A2 (en) * 2024-04-17 2025-10-23 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2025245071A1 (en) * 2024-05-21 2025-11-27 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2025247325A1 (en) * 2024-05-30 2025-12-04 Hanx Biopharmaceuticals, (Wuhan) Ltd. Antibody-drug conjugates targeting trbv12 and uses thereof
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells

Citations (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US861745A (en) 1906-11-21 1907-07-30 Jefferson D Maxwell Hydraulic dredging apparatus.
WO1986001533A1 (en) 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
JPS6153947U (enExample) 1984-09-13 1986-04-11
GB2188638A (en) 1986-03-27 1987-10-07 Gregory Paul Winter Chimeric antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
EP0368684A1 (en) 1988-11-11 1990-05-16 Medical Research Council Cloning immunoglobulin variable domain sequences.
EP0388151A1 (en) 1989-03-13 1990-09-19 Celltech Limited Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1991017271A1 (en) 1990-05-01 1991-11-14 Affymax Technologies N.V. Recombinant library screening methods
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
WO1992015679A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Improved epitode displaying phage
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0519596A1 (en) 1991-05-17 1992-12-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1993001288A1 (de) 1991-07-08 1993-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemid zum screenen von antikörpern
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
EP0616640A1 (en) 1991-12-02 1994-09-28 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5731116A (en) 1989-05-17 1998-03-24 Dai Nippon Printing Co., Ltd. Electrostatic information recording medium and electrostatic information recording and reproducing method
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5831012A (en) 1994-01-14 1998-11-03 Pharmacia & Upjohn Aktiebolag Bacterial receptor structures
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US5861155A (en) 1993-12-08 1999-01-19 Astra Ab Humanized antibodies and uses thereof
WO1999016873A1 (de) 1997-09-26 1999-04-08 Arne Skerra Anticaline
WO1999045110A1 (en) 1998-03-06 1999-09-10 Diatech Pty. Ltd. V-like domain binding molecules
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2000060070A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO2001004144A2 (de) 1999-07-13 2001-01-18 Scil Proteins Gmbh Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
WO2001064942A1 (en) 2000-02-29 2001-09-07 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6582915B1 (en) 1991-12-02 2003-06-24 Medical Research Council Production of anti-self bodies from antibody segment repertories and displayed on phage
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
US20040009530A1 (en) 2002-01-16 2004-01-15 Wilson David S. Engineered binding proteins
US6696245B2 (en) 1997-10-20 2004-02-24 Domantis Limited Methods for selecting functional polypeptides
WO2004058821A2 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
WO2004101790A1 (en) 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
WO2004106368A1 (de) 2003-05-28 2004-12-09 Scil Proteins Gmbh Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US7083785B2 (en) 1999-08-17 2006-08-01 Biogen Idcc MA Inc. Methods of treatment by administering an anti-BCMA antibody
WO2006079372A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
WO2006121168A1 (en) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US7183076B2 (en) 1997-05-02 2007-02-27 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US7276241B2 (en) 1999-10-06 2007-10-02 Biogen Idec Ma Inc. Methods of treating a tumor that expresses APRIL by administering BCMA
EP1870459A1 (en) 2005-03-31 2007-12-26 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US20080069820A1 (en) 2006-08-30 2008-03-20 Genentech, Inc. Multispecific antibodies
US7431380B1 (en) 2005-02-24 2008-10-07 Theodore Allen Buresh Louver kit
US20080247944A1 (en) 2005-01-12 2008-10-09 Robert Graziano Irta-2 Antibodies and Their Uses
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US7642228B2 (en) 1995-03-01 2010-01-05 Genentech, Inc. Method for making heteromultimeric polypeptides
US20100028330A1 (en) 2002-12-23 2010-02-04 Medimmune Limited Methods of upmodulating adaptive immune response using anti-pd1 antibodies
WO2010019570A2 (en) 2008-08-11 2010-02-18 Medarex, Inc. Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2010027827A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
US7741446B2 (en) 2006-08-18 2010-06-22 Armagen Technologies, Inc. Fusion antibodies that cross the blood-brain barrier in both directions
US7750128B2 (en) 2004-09-24 2010-07-06 Amgen Inc. Modified Fc molecules
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7799902B2 (en) 2004-03-23 2010-09-21 Biogen Idec Ma Inc. Receptor coupling agents and compositions thereof
US20100316645A1 (en) 2009-06-16 2010-12-16 Sabine Imhof-Jung Bispecific Antigen Binding Proteins
US7855275B2 (en) 2004-09-23 2010-12-21 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20110054151A1 (en) 2009-09-02 2011-03-03 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US7919257B2 (en) 2003-05-30 2011-04-05 Merus Biopharmaceuticals, B.V.I.O. Method for selecting a single cell expressing a heterogeneous combination of antibodies
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US20110177093A1 (en) 2002-02-21 2011-07-21 Biogen, Inc. Use of bcma as an immunoregulatory agent
US20110177073A1 (en) 2002-07-18 2011-07-21 Merus B.V. Recombinant production of mixtures of antibodies
US7999077B2 (en) 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
US8003774B2 (en) 2003-01-09 2011-08-23 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20110293613A1 (en) 2010-03-26 2011-12-01 Ulrich Brinkmann Bispecific antibodies
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
US20120039906A1 (en) 2009-02-09 2012-02-16 INSER (Institut National de la Recherche Medicale) PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof
US20120114649A1 (en) 2008-08-25 2012-05-10 Amplimmune, Inc. Delaware Compositions of pd-1 antagonists and methods of use
US20120149876A1 (en) 2010-11-05 2012-06-14 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
US20120184716A1 (en) 2010-08-16 2012-07-19 Novlmmune S.A. Methods for the Generation of Multispecific and Multivalent Antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US20120213768A1 (en) 2011-02-19 2012-08-23 Baylor Research Institute Diagnostic and Therapeutic Uses for B Cell Maturation Antigen
US8354509B2 (en) 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1
US20130017200A1 (en) 2009-12-04 2013-01-17 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US20130022601A1 (en) 2009-04-07 2013-01-24 Ulrich Brinkmann Trivalent, bispecific antibodies
US8362213B2 (en) 2009-04-01 2013-01-29 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
US20130078249A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
WO2013079174A1 (en) 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
US8466260B2 (en) 2009-04-01 2013-06-18 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
US20130165638A1 (en) 2011-12-27 2013-06-27 Development Center For Biotechnology Light chain-bridged bispecific antibody
US20130178605A1 (en) 2011-03-25 2013-07-11 Stanislas Blein Hetero-Dimeric Immunoglobulins
US20130195849A1 (en) 2011-11-04 2013-08-01 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
US20130243775A1 (en) 2012-03-14 2013-09-19 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
US20130266568A1 (en) 2010-08-24 2013-10-10 Roche Glycart Ag Activatable bispecific antibodies
US20130267686A1 (en) 2010-08-24 2013-10-10 Hoffmann-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized - fv fragment
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
US8580252B2 (en) 2004-03-05 2013-11-12 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20130303396A1 (en) 2008-04-11 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8586713B2 (en) 2009-06-26 2013-11-19 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US20130317200A1 (en) 2011-10-19 2013-11-28 Novlmmune S.A. Methods of Purifying Antibodies
US8602269B2 (en) 2009-09-14 2013-12-10 Guala Dispensing S.P.A. Trigger sprayer
WO2014008218A1 (en) 2012-07-02 2014-01-09 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
US20140037621A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
US20140051833A1 (en) 2012-03-13 2014-02-20 Novlmmune S.A. Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
US20140051835A1 (en) 2012-06-25 2014-02-20 Zymeworks Inc. Process and Methods for Efficient Manufacturing of Highly Pure Asymmetric Antibodies in Mammalian Cells
EP2699259A1 (en) 2011-04-21 2014-02-26 Boehringer Ingelheim International GmbH Bcma-based stratification and therapy for multiple myeloma patients
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
US20140079689A1 (en) 2011-02-04 2014-03-20 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
US20140154254A1 (en) 2012-11-21 2014-06-05 Amgen Inc. Heterodimeric immunoglobulins
US20140199294A1 (en) 2011-06-30 2014-07-17 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US20140200331A1 (en) 2012-11-28 2014-07-17 Zymeworks Inc. Engineered Immunoglobulin Heavy Chain-Light Chain Pairs And Uses Thereof
US20140242075A1 (en) 2011-05-30 2014-08-28 Genmab B.V. Antibody variants and uses thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
US8821883B2 (en) 2003-03-28 2014-09-02 Biogen Idec Ma Inc. Method of treating B cell cancers by administering truncated BAFF receptors
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
US20140322221A1 (en) 2000-04-11 2014-10-30 Genentech, Inc. Multivalent antibodies and uses therefor
US20140348839A1 (en) 2011-12-20 2014-11-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
US20140363426A1 (en) 2013-03-15 2014-12-11 Gregory Moore Heterodimeric proteins
US20140377269A1 (en) 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
US8920776B2 (en) 2002-01-22 2014-12-30 Corixa Corporation Compositions and methods for the detection diagnosis and therapy of hematological malignancies
US20150017187A1 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US20150018529A1 (en) 2012-02-22 2015-01-15 Ucb Pharma S.A. Sequence Symmetric Modified IgG4 Bispecific Antibodies
EP2847231A1 (en) 2012-05-10 2015-03-18 Bioatla LLC Multi-specific monoclonal antibodies
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20150098900A1 (en) 2013-06-24 2015-04-09 Genentech, Inc. Anti-fcrh5 antibodies
US20150133638A1 (en) 2012-02-10 2015-05-14 Genentech, Inc. Single-chain antibodies and other heteromultimers
US9034324B2 (en) 2009-03-10 2015-05-19 Biogen Idec Ma Inc. Anti-BCMA antibodies
US20150166670A1 (en) 2012-05-24 2015-06-18 Hoffmann-La Roche Inc. Multispecific antibodies
US20150166661A1 (en) 2013-12-17 2015-06-18 Genentech, Inc. Anti-cd3 antibodies and methods of use
US20150175707A1 (en) 2012-07-06 2015-06-25 Genmab B.V. Dimeric protein with triple mutations
WO2015107025A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding properties
WO2015107015A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
US20150211001A1 (en) 2012-10-03 2015-07-30 Jason Baardsnes Methods of quantitating heavy and light chain polypeptide pairs
US20150232560A1 (en) 2012-06-27 2015-08-20 Hoffmann-La Roche Inc. Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
WO2015127158A1 (en) 2014-02-21 2015-08-27 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
US9145588B2 (en) 2011-09-26 2015-09-29 Merus Biopharmaceuticals B.V. Generation of binding molecules
US20150315296A1 (en) 2014-04-02 2015-11-05 Hoffmann-La Roche Inc. Multispecific antibodies
US9200060B2 (en) 2009-11-23 2015-12-01 Amgen Inc. Monomeric antibody Fc
WO2015181805A1 (en) 2014-05-28 2015-12-03 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
US20150344570A1 (en) 2012-12-27 2015-12-03 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US20150353636A1 (en) 2013-01-10 2015-12-10 Genmab B.V. Human igg1 fc region variants and uses thereof
US20150368352A1 (en) 2013-02-08 2015-12-24 Stemcentrx, Inc. Novel multispecific constructs
US20150368351A1 (en) 2013-02-05 2015-12-24 Engmab Ag Method for the selection of antibodies against bcma
WO2015197598A2 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
US20160015749A1 (en) 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
WO2016016299A1 (en) 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
EP2982694A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against cd3epsilon and bcma
US20160039947A1 (en) 2013-03-15 2016-02-11 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
WO2016026943A1 (en) 2014-08-20 2016-02-25 Argen-X N.V Asymmetric multispecific antibodies
US20160075785A1 (en) 2014-08-04 2016-03-17 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
US9309311B2 (en) 2009-04-27 2016-04-12 Oncomed Pharmaceuticals, Inc. Method for making Heteromultimeric molecules
US20160102135A1 (en) 2013-05-31 2016-04-14 Zymeworks Inc. Heteromultimers with reduced or silenced effector function
US20160114057A1 (en) 2013-05-24 2016-04-28 Zyeworks Inc. Modular protein drug conjugate therapeutic
US20160131654A1 (en) 2013-02-08 2016-05-12 Institute For Myeloma & Bone Cancer Research Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
US20160130347A1 (en) 2012-10-08 2016-05-12 Roche Glycart Ag Fc-free antibodies comprising two Fab-fragments and methods of use
WO2016071377A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and protein a-binding properties
WO2016071376A2 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
US9340621B2 (en) 2011-11-15 2016-05-17 Boehringer Ingelheim International Gmbh Binding molecules for BCMA and CD3
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
US20160145340A1 (en) 2013-03-15 2016-05-26 Amegen Inc. Bispecific-fc molecules
WO2016079081A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
US9359437B2 (en) 2013-02-01 2016-06-07 Regeneron Pharmaceuticals, Inc. Antibodies comprising chimeric constant domains
US9358286B2 (en) 2012-04-20 2016-06-07 Merus B.V. Methods and means for the production of IG-like molecules
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
WO2016090327A2 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
US20160176973A1 (en) 2013-03-15 2016-06-23 Amgen Research (Munich) Gmbh Binding molecules for bcma and cd3
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US20160194389A1 (en) 2013-04-29 2016-07-07 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
US9387237B2 (en) 2003-10-20 2016-07-12 Biogen Ma Inc. Methods of treating a patient having an autoimmune disorder by administering a soluble BCMA
WO2016110584A1 (en) 2015-01-08 2016-07-14 Biontech Ag Agonistic tnf receptor binding agents
WO2016115274A1 (en) 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2016118641A1 (en) 2015-01-20 2016-07-28 Igm Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
US20160229915A1 (en) 2013-09-27 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
EP3055329A1 (en) 2013-10-11 2016-08-17 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
US20160257763A1 (en) 2012-05-10 2016-09-08 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US20160264685A1 (en) 2015-03-13 2016-09-15 Novimmune Sa Methods of purifying bispecific antibodies
US20160297885A1 (en) 2015-04-13 2016-10-13 Pfizer Inc. Therapeutic antibodies and their uses
WO2016168149A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
US20160311915A1 (en) 2013-10-10 2016-10-27 Ucl Business Plc Molecule
US20160368988A1 (en) 2015-07-10 2016-12-22 Merus N.V. Human cd3 binding antibody
US20160368985A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE
US9545086B2 (en) 1999-01-25 2017-01-17 Biogen Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20170022284A1 (en) 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
WO2017021450A1 (en) 2015-08-03 2017-02-09 Engmab Ag Monoclonal antibodies against bcma
US20170037128A1 (en) 2014-04-13 2017-02-09 Affimed Gmbh Trifunctional antigen-binding molecule
US20170051068A1 (en) 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-BCMA Antibodies, Bispecific Antigen Binding Molecules that Bind BCMA and CD3, and Uses Thereof
EP3137500A1 (en) 2014-04-30 2017-03-08 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Humanized antibodies against cd269 (bcma)
WO2018057955A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains

Family Cites Families (440)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
JPH021556A (ja) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd ハイブリッド抗体及びその作製方法
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5116615A (en) 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5747036A (en) 1991-08-28 1998-05-05 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
CA2128511C (en) 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2135408A1 (en) 1992-05-08 1993-11-25 Peter C. Keck Chimeric multivalent protein analogues and methods of use thereof
JP3980657B2 (ja) 1992-06-26 2007-09-26 生化学工業株式会社 コンドロイチナーゼａｂｃ、その製造法及び医薬組成物
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
DE69334238D1 (de) 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH0787994A (ja) 1993-04-30 1995-04-04 Sumitomo Electric Ind Ltd Ｔ細胞抗原受容体Ｖβ２２に対するモノクローナル抗体及びその製造方法
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
DE69433970T2 (de) 1993-08-10 2005-08-11 W.L. Gore & Associates, Inc., Newark Zelleinkapselungsvorrichtung
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6017719A (en) 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
AU712441B2 (en) 1994-12-14 1999-11-04 Scripps Research Institute, The In vivo activation of tumor-specific cytotoxic T cells
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996037621A2 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Multimeric proteins
JPH10503964A (ja) 1995-06-07 1998-04-14 ゴア ハイブリッド テクノロジーズ，インコーポレイティド 治療用デバイスのための移植可能な閉じ込め装置並びにその中にそのデバイスを装填及び再装填する方法
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU6854696A (en) 1995-09-22 1997-04-09 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
WO1997038102A1 (en) 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
NZ330995A (en) 1996-10-04 2000-12-22 Univ Jefferson Generation of T cells mediating an immune response and use for treating cancer
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
AU736707B2 (en) 1997-06-11 2001-08-02 Anaphore, Inc. Trimerising module
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
DE69837706T2 (de) 1997-07-21 2008-01-10 Active Biotech Ab Zytolyse der geeigneten zielzellen mit superantigen konjugate mittels der induktion von t-zell aktivierung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
EP1049787B1 (en) 1998-01-23 2004-11-24 Vlaams Interuniversitair Instituut voor Biotechnologie Multipurpose antibody derivatives
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
ES2207278T3 (es) 1998-07-28 2004-05-16 Micromet Ag Heterominicuerpos.
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US6979546B2 (en) 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
ES2321687T3 (es) 1999-11-15 2009-06-10 Innate Pharma Receptor activador implicado en la citotoxicidad natural mediada por las celulas destructoras naturales humanas y anticuerpos que identifican dicho receptor.
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
WO2001053354A2 (en) 2000-01-20 2001-07-26 Chiron Corporation Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1297017B1 (en) 2000-06-19 2012-06-13 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
IL137419A0 (en) 2000-07-20 2001-07-24 Yissum Res Dev Co Nk cells activating receptors and their therapeutic and diagnostic uses
EP1309705B1 (en) 2000-07-25 2012-02-15 Immunomedics Inc. Multivalent target binding protein
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CN1308447C (zh) 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002070647A2 (en) 2001-03-05 2002-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses
WO2002072635A2 (en) 2001-03-13 2002-09-19 University College London Specific binding members
AU2002258808A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
ATE346866T1 (de) 2001-09-14 2006-12-15 Affimed Therapeutics Ag Multimerische, einzelkettige, tandem-fv- antikörper
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US20030211078A1 (en) 2001-12-07 2003-11-13 Heavner George A. Pseudo-antibody constructs
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2471551C (en) 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
EP1500665B1 (en) 2002-04-15 2011-06-15 Chugai Seiyaku Kabushiki Kaisha METHODS FOR CONSTRUCTING scDb LIBRARIES
AU2003233197A1 (en) 2002-04-29 2003-11-17 Genpat77 Pharmacogenetics Ag Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
US7829289B2 (en) 2002-05-14 2010-11-09 Institut National De La Sante Et De Recherche Medicale T cell subpopulation regulating gut immunity
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7906118B2 (en) 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
EP1539966B1 (en) 2002-09-12 2010-06-30 Greenovation Biotech GmbH Protein production method
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2509400A1 (en) 2002-12-09 2004-06-24 Natspears Ltd. Nk cell receptor conjugates for treating malignancies
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
AU2003294912B2 (en) 2002-12-20 2009-06-04 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
AU2003294930B2 (en) 2002-12-23 2008-12-04 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
WO2005028517A2 (en) 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US20070105105A1 (en) 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
HUE033129T2 (en) 2003-07-24 2017-11-28 Innate Pharma Sa Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005062916A2 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2005105848A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for enhancing nk cell activity
WO2005105849A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for treating proliferative disorders such as nk-type ldgl
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
ES2432141T3 (es) 2005-01-27 2013-11-29 Novartis Vaccines And Diagnostics, Inc. Procedimientos para tratar carcinoma de células renales
CA2604032C (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
AU2006237329B2 (en) 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
CN103145837A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
WO2007016130A2 (en) 2005-07-27 2007-02-08 Lipid Sciences, Inc. A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1757622B1 (en) 2005-08-26 2009-12-23 PLS Design GmbH Bivalent IgY antibody constructs for diagnostic and therapeutic applications
ME02705B (me) * 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
US20090010843A1 (en) 2005-09-23 2009-01-08 Novo Nordisk A/S Methods of Identifying Antibodies to Ligands of Orphan Receptors
WO2007042809A2 (en) 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
WO2007047335A2 (en) 2005-10-13 2007-04-26 Biogen Idec Ma Inc. Methods for use with baff antagonists
EP1934260B1 (en) 2005-10-14 2017-05-17 Innate Pharma Compositions and methods for treating proliferative disorders
EP1945771A1 (en) 2005-10-28 2008-07-23 Novo Nordisk A/S Fusion proteins that bind effector lymphocytes and target cells
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1962961B1 (en) 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2638794A1 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Functional antibodies
WO2007101949A2 (fr) 2006-03-08 2007-09-13 Biomethodes Variants de l'interferon- gamma humain (infgamma)
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
WO2007112362A2 (en) 2006-03-24 2007-10-04 The Regents Of The University Of California Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2799449A1 (en) 2006-05-25 2014-11-05 Bayer Intellectual Property GmbH Dimeric molecular complexes
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
WO2008017859A2 (en) 2006-08-10 2008-02-14 Isis Innovation Limited Ligand for the g6b receptor on blood platelets
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
WO2008033403A2 (en) 2006-09-13 2008-03-20 The Trustees Of Columbia University In The City Of New York Agents and methods to elicit anti-tumor immune response
WO2008140477A2 (en) 2006-11-02 2008-11-20 Capon Daniel J Hybrid immunoglobulins with moving parts
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008087219A1 (en) 2007-01-19 2008-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for regulating t cell activity
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2388266B1 (en) 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
CA2696263C (en) 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
US7858759B2 (en) 2007-10-04 2010-12-28 Zymogenetics, Inc. Anti-zB7H6 antibody-drug conjugates
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
JP5737944B2 (ja) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2009103538A1 (en) 2008-02-21 2009-08-27 Baxter International Inc. Procedure for the generation of a high producer cell line for the expression of a recombinant anti-cd34 antibody
WO2010031168A1 (en) 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
JP2011524743A (ja) 2008-06-02 2011-09-08 アンスティテュ・グスターブ・ルシ ナチュラルキラーｐ３０（ＮＫｐ３０）機能障害及びその生物学的用途
CA2735193A1 (en) 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
WO2010078916A1 (en) 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
US8497071B2 (en) 2009-06-29 2013-07-30 California Institute Of Technology Isolation of unknown rearranged T-cell receptors from single cells
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012006443A (es) 2009-12-09 2012-06-28 Inst Nat Sante Rech Med Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos.
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
PL2530091T3 (pl) 2010-01-29 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
US9018006B2 (en) 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
CN101985476B (zh) 2010-10-29 2012-11-21 中国科学技术大学 抗人NKp30单克隆抗体的制备、鉴定及应用
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012088309A1 (en) 2010-12-21 2012-06-28 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2014520123A (ja) 2011-06-17 2014-08-21 アムジエン・インコーポレーテツド Ｃｌｅｃ−２を使用して代謝性障害を治療または改善させる方法
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
BR112014009866A2 (pt) 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos
IN2014CN03887A (enExample) 2011-10-27 2015-10-16 Genmab As
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
CN104203981A (zh) 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
JP6153947B2 (ja) 2012-01-05 2017-06-28 ヴィザ インターナショナル サーヴィス アソシエイション 取引映像キャプチャ装置、方法およびシステム
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
PL3434695T3 (pl) 2012-08-07 2021-05-17 Roche Glycart Ag Ulepszona immunoterapia
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
US20140079691A1 (en) 2012-09-20 2014-03-20 Anaptysbio, Inc. Thermostable antibody framework regions
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
JP6359031B2 (ja) 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CA2906566C (en) 2013-03-14 2024-09-10 Macrogenics, Inc. Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
MX366978B (es) 2013-03-15 2019-08-01 Novartis Ag Conjugados de anticuerpo - farmaco.
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
EP2808338B1 (en) 2013-09-16 2016-03-30 CeMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Mutant calreticulin for the diagnosis of myeloid malignancies
CN106795220A (zh) 2013-10-30 2017-05-31 建新公司 通过αβTCR结合多肽的多重施用的用于增强免疫抑制疗法的方法
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
RU2744046C2 (ru) 2014-03-05 2021-03-02 Отолус Лимитед ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА
RU2752933C2 (ru) 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
CN107172880B (zh) 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
BR112017004270B1 (pt) 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3868388A1 (en) 2014-10-03 2021-08-25 Oxford University Innovation Limited Analysis of t-cell monotypia
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
WO2016090337A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
US9767555B2 (en) 2015-01-05 2017-09-19 Case Western Reserve University Disease characterization from fused pathology and radiology data
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2016176756A1 (en) 2015-05-05 2016-11-10 University Health Network Nk cells and antibodies for cancer treatment
HRP20191800T1 (hr) 2015-05-13 2019-12-27 Ablynx N.V. Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti
WO2016193300A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
KR20180020202A (ko) * 2015-06-01 2018-02-27 메디진 이뮤노테라피스 게엠바하 T 세포 수용체 특이적 항체
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
US20170096485A1 (en) 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
JP7461620B2 (ja) 2015-10-06 2024-04-04 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療用化合物及び方法
CN108283001B (zh) 2015-10-08 2022-08-19 酵活有限公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2017167350A1 (en) 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
CA2937157A1 (en) 2016-07-25 2018-01-25 Ucl Business Ltd Protein-based t-cell receptor knockdown
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
CA3051866A1 (en) 2017-02-01 2018-08-09 Nant Holdings Ip, Llc Calreticulin-mediated cancer treatment
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2018193103A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-psma antibody-drug conjugate
EP4328241A3 (en) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
AU2018290272A1 (en) 2017-06-21 2020-01-30 Gsbio, Llc Heterodimeric bispecific antibodies
TW201904588A (zh) 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
WO2019017940A1 (en) 2017-07-19 2019-01-24 Rubius Therapeutics, Inc. COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASE
SG11202000820PA (en) 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US10578740B2 (en) 2017-08-23 2020-03-03 Mezmeriz Inc. Coherent optical distance measurement apparatus and method
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
MX2020002880A (es) 2017-09-14 2020-10-01 Dragonfly Therapeutics Inc Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1).
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
GB201718088D0 (en) 2017-11-01 2017-12-13 Autolus Ltd Vectors
EP3713959A1 (en) 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
US11970537B2 (en) 2017-12-26 2024-04-30 Nanjing GenScript Biotech Co., Ltd. Fusion protein dimer using antibody Fc region as backbone and use thereof
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
GB201800298D0 (en) 2018-01-09 2018-02-21 Autolus Ltd Method
EP3752178A1 (en) 2018-02-16 2020-12-23 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
KR20260100427A (ko) 2018-03-28 2026-06-29 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
CN112384534A (zh) 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
BR112020025287A2 (pt) 2018-06-25 2021-03-09 University Of Washington Projeto de novo de miméticos de interleucina potentes e seletivos
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020018708A1 (en) 2018-07-18 2020-01-23 The General Hospital Corporation Compositions and methods for treatment of t cell malignancies
CN108949698B (zh) 2018-07-31 2019-05-31 广东和信健康科技有限公司 杂交瘤细胞株c11-6f7及其产生的hcmv单克隆抗体和应用
GB201812650D0 (en) 2018-08-03 2018-09-19 Autolus Ltd Molecular assessment of TRBC usage
BR112021002032A2 (pt) 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3098930A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
CA3114179A1 (en) 2018-09-28 2020-04-02 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
EP3866842A4 (en) 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
CA3117853A1 (en) 2018-10-29 2020-05-07 1Globe Biomedical Co., Ltd. Novel rationally designed protein compositions
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
JP2022511390A (ja) 2018-11-20 2022-01-31 ユニバーシティ オブ ワシントン 分割インターロイキン模倣体およびその使用
RU2712251C1 (ru) 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
AR117735A1 (es) 2018-12-25 2021-08-25 Joint Stock Company “Biocad” ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO
JP7700039B2 (ja) 2019-01-04 2025-06-30 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
SG11202109122SA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
MX2021010441A (es) 2019-03-01 2021-09-21 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
CN119954959A (zh) 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
US20230340122A1 (en) 2019-11-05 2023-10-26 Glaxosmithkline Intellectual Property (No. 4) Ltd. Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
CN115003698A (zh) 2019-11-14 2022-09-02 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
KR20220147583A (ko) 2020-01-09 2022-11-03 바이오뮤넥스 파마슈티컬스 Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체
EP4121518A4 (en) 2020-03-16 2024-06-19 Marengo Therapeutics, Inc. MODIFIED CELL COMPOSITIONS AND METHODS OF USE
AU2021261420A1 (en) 2020-04-24 2022-12-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
JP2023539645A (ja) 2020-08-26 2023-09-15 マレンゴ・セラピューティクス，インコーポレーテッド Ｎｋｐ３０に結合する抗体分子およびその使用
US20240150460A1 (en) 2021-02-26 2024-05-09 Shenghe (China) Biopharmaceutical Co., Ltd. Anti-nkp30 antibody and application thereof
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
WO2022240688A1 (en) 2021-05-10 2022-11-17 Amgen Inc. Dosing regimen for combination therapy targeting dll3 and pd-1
WO2023081412A2 (en) 2021-11-05 2023-05-11 Marengo Therapeutics, Inc. Immune cell populations and uses thereof
EP4453039A4 (en) 2021-12-22 2025-12-17 Marengo Therapeutics Inc TCR-binding multifunctional molecules and uses thereof
EP4466019A4 (en) 2022-01-21 2026-01-07 Marengo Therapeutics Inc MULTIFUNCTIONAL MOLECULES COMPRISING A G6B BINDER AND/OR A CD34 BINDER AND THEIR USES
KR20250143365A (ko) 2022-10-12 2025-10-01 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
EP4601619A4 (en) 2022-10-12 2026-08-05 Marengo Therapeutics Inc MULTIFUNCTIONAL MOLECULES THAT BIND TO TCR AND THEIR USES
EP4683651A2 (en) 2023-03-21 2026-01-28 Marengo Therapeutics, Inc. Tcr targeting molecules and uses thereof
WO2024226532A2 (en) 2023-04-24 2024-10-31 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
CN121487747A (zh) 2023-04-27 2026-02-06 马伦戈治疗公司 使用与tcr结合的分子的组合疗法
WO2024254611A2 (en) 2023-06-09 2024-12-12 Marengo Therapeutics, Inc. Multispecific molecules binding to tcr and uses thereof

Patent Citations (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US861745A (en) 1906-11-21 1907-07-30 Jefferson D Maxwell Hydraulic dredging apparatus.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1986001533A1 (en) 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
JPS6153947U (enExample) 1984-09-13 1986-04-11
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188638A (en) 1986-03-27 1987-10-07 Gregory Paul Winter Chimeric antibodies
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
EP0368684A1 (en) 1988-11-11 1990-05-16 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
EP0388151A1 (en) 1989-03-13 1990-09-19 Celltech Limited Modified antibodies
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5731116A (en) 1989-05-17 1998-03-24 Dai Nippon Printing Co., Ltd. Electrostatic information recording medium and electrostatic information recording and reproducing method
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1991017271A1 (en) 1990-05-01 1991-11-14 Affymax Technologies N.V. Recombinant library screening methods
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
WO1992015679A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Improved epitode displaying phage
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
EP0519596A1 (en) 1991-05-17 1992-12-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1993001288A1 (de) 1991-07-08 1993-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemid zum screenen von antikörpern
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6582915B1 (en) 1991-12-02 2003-06-24 Medical Research Council Production of anti-self bodies from antibody segment repertories and displayed on phage
EP0616640A1 (en) 1991-12-02 1994-09-28 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6593081B1 (en) 1991-12-02 2003-07-15 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5861155A (en) 1993-12-08 1999-01-19 Astra Ab Humanized antibodies and uses thereof
US5831012A (en) 1994-01-14 1998-11-03 Pharmacia & Upjohn Aktiebolag Bacterial receptor structures
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7642228B2 (en) 1995-03-01 2010-01-05 Genentech, Inc. Method for making heteromultimeric polypeptides
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US7183076B2 (en) 1997-05-02 2007-02-27 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO1999016873A1 (de) 1997-09-26 1999-04-08 Arne Skerra Anticaline
US6696245B2 (en) 1997-10-20 2004-02-24 Domantis Limited Methods for selecting functional polypeptides
WO1999045110A1 (en) 1998-03-06 1999-09-10 Diatech Pty. Ltd. V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US9545086B2 (en) 1999-01-25 2017-01-17 Biogen Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
WO2000060070A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
WO2001004144A2 (de) 1999-07-13 2001-01-18 Scil Proteins Gmbh Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
US7083785B2 (en) 1999-08-17 2006-08-01 Biogen Idcc MA Inc. Methods of treatment by administering an anti-BCMA antibody
US7276241B2 (en) 1999-10-06 2007-10-02 Biogen Idec Ma Inc. Methods of treating a tumor that expresses APRIL by administering BCMA
US8299220B2 (en) 1999-11-29 2012-10-30 Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
WO2001064942A1 (en) 2000-02-29 2001-09-07 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20140322221A1 (en) 2000-04-11 2014-10-30 Genentech, Inc. Multivalent antibodies and uses therefor
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US20040009530A1 (en) 2002-01-16 2004-01-15 Wilson David S. Engineered binding proteins
US8920776B2 (en) 2002-01-22 2014-12-30 Corixa Corporation Compositions and methods for the detection diagnosis and therapy of hematological malignancies
US20110177093A1 (en) 2002-02-21 2011-07-21 Biogen, Inc. Use of bcma as an immunoregulatory agent
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
US20110177073A1 (en) 2002-07-18 2011-07-21 Merus B.V. Recombinant production of mixtures of antibodies
US20100028330A1 (en) 2002-12-23 2010-02-04 Medimmune Limited Methods of upmodulating adaptive immune response using anti-pd1 antibodies
WO2004058821A2 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US8003774B2 (en) 2003-01-09 2011-08-23 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8450470B2 (en) 2003-03-05 2013-05-28 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8772246B2 (en) 2003-03-05 2014-07-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8202517B2 (en) 2003-03-05 2012-06-19 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8821883B2 (en) 2003-03-28 2014-09-02 Biogen Idec Ma Inc. Method of treating B cell cancers by administering truncated BAFF receptors
WO2004101790A1 (en) 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
WO2004106368A1 (de) 2003-05-28 2004-12-09 Scil Proteins Gmbh Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
US7919257B2 (en) 2003-05-30 2011-04-05 Merus Biopharmaceuticals, B.V.I.O. Method for selecting a single cell expressing a heterogeneous combination of antibodies
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
WO2005035572A2 (en) 2003-10-08 2005-04-21 Domantis Limited Antibody compositions and methods
US9387237B2 (en) 2003-10-20 2016-07-12 Biogen Ma Inc. Methods of treating a patient having an autoimmune disorder by administering a soluble BCMA
US8580252B2 (en) 2004-03-05 2013-11-12 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7799902B2 (en) 2004-03-23 2010-09-21 Biogen Idec Ma Inc. Receptor coupling agents and compositions thereof
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
US7855275B2 (en) 2004-09-23 2010-12-21 Genentech, Inc. Cysteine engineered antibodies and conjugates
US7750128B2 (en) 2004-09-24 2010-07-06 Amgen Inc. Modified Fc molecules
US7999077B2 (en) 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
US20080247944A1 (en) 2005-01-12 2008-10-09 Robert Graziano Irta-2 Antibodies and Their Uses
WO2006079372A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7431380B1 (en) 2005-02-24 2008-10-07 Theodore Allen Buresh Louver kit
US20100015133A1 (en) 2005-03-31 2010-01-21 Chugai Seiyaku Kabushiki Kaisha Methods for Producing Polypeptides by Regulating Polypeptide Association
EP1870459A1 (en) 2005-03-31 2007-12-26 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2006121168A1 (en) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
US7741446B2 (en) 2006-08-18 2010-06-22 Armagen Technologies, Inc. Fusion antibodies that cross the blood-brain barrier in both directions
US20080069820A1 (en) 2006-08-30 2008-03-20 Genentech, Inc. Multispecific antibodies
US8354509B2 (en) 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US20130303396A1 (en) 2008-04-11 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010019570A2 (en) 2008-08-11 2010-02-18 Medarex, Inc. Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
US20110150892A1 (en) 2008-08-11 2011-06-23 Medarex, Inc. Human antibodies that bind lymphocyte activation gene-3 (lag-3) and uses thereof
US20120114649A1 (en) 2008-08-25 2012-05-10 Amplimmune, Inc. Delaware Compositions of pd-1 antagonists and methods of use
WO2010027827A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
US8609089B2 (en) 2008-08-25 2013-12-17 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US20120039906A1 (en) 2009-02-09 2012-02-16 INSER (Institut National de la Recherche Medicale) PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof
US9034324B2 (en) 2009-03-10 2015-05-19 Biogen Idec Ma Inc. Anti-BCMA antibodies
US8466260B2 (en) 2009-04-01 2013-06-18 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
US8362213B2 (en) 2009-04-01 2013-01-29 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
US8617559B2 (en) 2009-04-01 2013-12-31 Genetech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US20130022601A1 (en) 2009-04-07 2013-01-24 Ulrich Brinkmann Trivalent, bispecific antibodies
US9309311B2 (en) 2009-04-27 2016-04-12 Oncomed Pharmaceuticals, Inc. Method for making Heteromultimeric molecules
US20100316645A1 (en) 2009-06-16 2010-12-16 Sabine Imhof-Jung Bispecific Antigen Binding Proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
US8586713B2 (en) 2009-06-26 2013-11-19 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US20110054151A1 (en) 2009-09-02 2011-03-03 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8602269B2 (en) 2009-09-14 2013-12-10 Guala Dispensing S.P.A. Trigger sprayer
US9200060B2 (en) 2009-11-23 2015-12-01 Amgen Inc. Monomeric antibody Fc
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US20130017200A1 (en) 2009-12-04 2013-01-17 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US20110293613A1 (en) 2010-03-26 2011-12-01 Ulrich Brinkmann Bispecific antibodies
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2581113A1 (en) 2010-06-11 2013-04-17 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
US20140044728A1 (en) 2010-06-11 2014-02-13 Kyushu University, National University Corporation Anti-tim-3 antibody
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
US8552156B2 (en) 2010-06-11 2013-10-08 Kyowa Hakko Kirin Co., Ltd Anti-TIM-3 antibody
US20120184716A1 (en) 2010-08-16 2012-07-19 Novlmmune S.A. Methods for the Generation of Multispecific and Multivalent Antibodies
US20130266568A1 (en) 2010-08-24 2013-10-10 Roche Glycart Ag Activatable bispecific antibodies
US20130267686A1 (en) 2010-08-24 2013-10-10 Hoffmann-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized - fv fragment
US20120149876A1 (en) 2010-11-05 2012-06-14 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US20140079689A1 (en) 2011-02-04 2014-03-20 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
US20120213768A1 (en) 2011-02-19 2012-08-23 Baylor Research Institute Diagnostic and Therapeutic Uses for B Cell Maturation Antigen
US20130178605A1 (en) 2011-03-25 2013-07-11 Stanislas Blein Hetero-Dimeric Immunoglobulins
EP2699259A1 (en) 2011-04-21 2014-02-26 Boehringer Ingelheim International GmbH Bcma-based stratification and therapy for multiple myeloma patients
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
US20140242075A1 (en) 2011-05-30 2014-08-28 Genmab B.V. Antibody variants and uses thereof
US20140199294A1 (en) 2011-06-30 2014-07-17 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US20130078249A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
US9145588B2 (en) 2011-09-26 2015-09-29 Merus Biopharmaceuticals B.V. Generation of binding molecules
US20130317200A1 (en) 2011-10-19 2013-11-28 Novlmmune S.A. Methods of Purifying Antibodies
US20130195849A1 (en) 2011-11-04 2013-08-01 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
US9340621B2 (en) 2011-11-15 2016-05-17 Boehringer Ingelheim International Gmbh Binding molecules for BCMA and CD3
WO2013079174A1 (en) 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
US20140348839A1 (en) 2011-12-20 2014-11-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
US20130165638A1 (en) 2011-12-27 2013-06-27 Development Center For Biotechnology Light chain-bridged bispecific antibody
US20150133638A1 (en) 2012-02-10 2015-05-14 Genentech, Inc. Single-chain antibodies and other heteromultimers
US20150018529A1 (en) 2012-02-22 2015-01-15 Ucb Pharma S.A. Sequence Symmetric Modified IgG4 Bispecific Antibodies
US20140051833A1 (en) 2012-03-13 2014-02-20 Novlmmune S.A. Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
US20130243775A1 (en) 2012-03-14 2013-09-19 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
US9358286B2 (en) 2012-04-20 2016-06-07 Merus B.V. Methods and means for the production of IG-like molecules
US20160257763A1 (en) 2012-05-10 2016-09-08 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
EP2847231A1 (en) 2012-05-10 2015-03-18 Bioatla LLC Multi-specific monoclonal antibodies
US20150166670A1 (en) 2012-05-24 2015-06-18 Hoffmann-La Roche Inc. Multispecific antibodies
US20140051835A1 (en) 2012-06-25 2014-02-20 Zymeworks Inc. Process and Methods for Efficient Manufacturing of Highly Pure Asymmetric Antibodies in Mammalian Cells
US20150232560A1 (en) 2012-06-27 2015-08-20 Hoffmann-La Roche Inc. Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
WO2014008218A1 (en) 2012-07-02 2014-01-09 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
US20150175707A1 (en) 2012-07-06 2015-06-25 Genmab B.V. Dimeric protein with triple mutations
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
US20140037621A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
US20150211001A1 (en) 2012-10-03 2015-07-30 Jason Baardsnes Methods of quantitating heavy and light chain polypeptide pairs
US20160130347A1 (en) 2012-10-08 2016-05-12 Roche Glycart Ag Fc-free antibodies comprising two Fab-fragments and methods of use
US20140154254A1 (en) 2012-11-21 2014-06-05 Amgen Inc. Heterodimeric immunoglobulins
US20140200331A1 (en) 2012-11-28 2014-07-17 Zymeworks Inc. Engineered Immunoglobulin Heavy Chain-Light Chain Pairs And Uses Thereof
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
US20140377269A1 (en) 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
US20150344570A1 (en) 2012-12-27 2015-12-03 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US20150353636A1 (en) 2013-01-10 2015-12-10 Genmab B.V. Human igg1 fc region variants and uses thereof
US20150337049A1 (en) 2013-01-10 2015-11-26 Genmab B.V. Inert format
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
US9359437B2 (en) 2013-02-01 2016-06-07 Regeneron Pharmaceuticals, Inc. Antibodies comprising chimeric constant domains
US20150376287A1 (en) 2013-02-05 2015-12-31 Engmab Ag Bispecific antibodies against cd3 and bcma
US20150368351A1 (en) 2013-02-05 2015-12-24 Engmab Ag Method for the selection of antibodies against bcma
US20160131654A1 (en) 2013-02-08 2016-05-12 Institute For Myeloma & Bone Cancer Research Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
US20150368352A1 (en) 2013-02-08 2015-12-24 Stemcentrx, Inc. Novel multispecific constructs
US20160015749A1 (en) 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
US20140363426A1 (en) 2013-03-15 2014-12-11 Gregory Moore Heterodimeric proteins
US20160145340A1 (en) 2013-03-15 2016-05-26 Amegen Inc. Bispecific-fc molecules
US20160039947A1 (en) 2013-03-15 2016-02-11 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
US20160176973A1 (en) 2013-03-15 2016-06-23 Amgen Research (Munich) Gmbh Binding molecules for bcma and cd3
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20160194389A1 (en) 2013-04-29 2016-07-07 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
US20160114057A1 (en) 2013-05-24 2016-04-28 Zyeworks Inc. Modular protein drug conjugate therapeutic
US20160102135A1 (en) 2013-05-31 2016-04-14 Zymeworks Inc. Heteromultimers with reduced or silenced effector function
US20150098900A1 (en) 2013-06-24 2015-04-09 Genentech, Inc. Anti-fcrh5 antibodies
US20150017187A1 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US20160229915A1 (en) 2013-09-27 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US20160311915A1 (en) 2013-10-10 2016-10-27 Ucl Business Plc Molecule
EP3055329A1 (en) 2013-10-11 2016-08-17 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
US20150166661A1 (en) 2013-12-17 2015-06-18 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2015107025A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding properties
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015107015A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
WO2015127158A1 (en) 2014-02-21 2015-08-27 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
US20150315296A1 (en) 2014-04-02 2015-11-05 Hoffmann-La Roche Inc. Multispecific antibodies
US20170037128A1 (en) 2014-04-13 2017-02-09 Affimed Gmbh Trifunctional antigen-binding molecule
EP3137500A1 (en) 2014-04-30 2017-03-08 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Humanized antibodies against cd269 (bcma)
WO2015181805A1 (en) 2014-05-28 2015-12-03 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
WO2015197598A2 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
WO2016016299A1 (en) 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
US20160075785A1 (en) 2014-08-04 2016-03-17 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
EP2982694A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against cd3epsilon and bcma
WO2016026943A1 (en) 2014-08-20 2016-02-25 Argen-X N.V Asymmetric multispecific antibodies
WO2016071376A2 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
WO2016071377A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and protein a-binding properties
WO2016079081A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
WO2016090327A2 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
WO2016110584A1 (en) 2015-01-08 2016-07-14 Biontech Ag Agonistic tnf receptor binding agents
WO2016115274A1 (en) 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2016118641A1 (en) 2015-01-20 2016-07-28 Igm Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
US20160264685A1 (en) 2015-03-13 2016-09-15 Novimmune Sa Methods of purifying bispecific antibodies
WO2016168149A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
US20160297885A1 (en) 2015-04-13 2016-10-13 Pfizer Inc. Therapeutic antibodies and their uses
US20160368985A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE
US20160368988A1 (en) 2015-07-10 2016-12-22 Merus N.V. Human cd3 binding antibody
US20170022284A1 (en) 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
WO2017021450A1 (en) 2015-08-03 2017-02-09 Engmab Ag Monoclonal antibodies against bcma
US20170051068A1 (en) 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-BCMA Antibodies, Bispecific Antigen Binding Molecules that Bind BCMA and CD3, and Uses Thereof
WO2018057955A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains

Non-Patent Citations (72)

* Cited by examiner, † Cited by third party
Title
(1970) J. Mol. Biol. 48:444-453
Adachi O. et al., 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 9(1):143-50
Agostinis, P. et al. (2011) CA Cancer J. Clin. 61 :250-281)
Akira et al., Europäische Patentanmeldung 184,187; Taniguchi, M., Europäische Patentanmeldung 171,496
Altschul et al. (1997), Nucleic Acids Res. 25:3389-3402
ay et al. (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281
Barbas et al. (1991) PNAS 88:7978-7982
Berg et al., Transplant Proc. 30(8):3975-3977, 1998; Haanen et al., J. Exp. Med. 190(9):13191328, 1999; Garland et al., J. Immunol Meth. 227(1-2):53-63, 1999
Bruggeman et al. 1991 Eur JImmunol 21:1323-1326
Bruggeman et al. 1993 Year Immunol 7:33-40; Tuaillon et al. 1993 PNAS 90:3720-3724
Cabilly et al., Europäische Patentanmeldung 125,023; Better et al. (1988 Science 240:1041-1043)
Chao et al. (2006) Nature Protocols 1(2):755-68
Chothia et al., (1992) J.Mol. Biol. 227:799-817; Tomlinson et al., (1992) J.Mol. Biol. 227:776-798
Clackson et al. (1991) Nature 352:624-628
Colcher, D. et al. (1999) Ann NY Acad Sci 880:263-80; und Reiter, Y. (1996) Clin. Cancer.Res 2:245-52
Costa-Mattioli M. & Sonenberg N. 2008. RAPping production of type I interferon in pDCs through mTOR. Nature Immunol. 9: 1097-1099
Doyle S. et al., 2002. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 17(3):251-63)
Eur J Immunol. 2001 Sep; 31(9):2680-9 „Recognition of viral hemagglutinins by NKp44 but not by NKp30"
Front Immunol. 2013; 4: 76
Frost und Stern, „A Microtiter-Based Assay for Hyaluronidase Activity Not Requiring Specialized Reagents", Analytical Biochemistry, Bd. 251, S. 263-269 (1997)
Fuchs et al. (1991) BiolTechnology 9:1370-1372
Garrad et al. (1991) BiolTechnology 9:1373-1377
Gram et al. (1992) PNAS 89:3576-3580
Green, L.L. et al. 1994 Nature Genet. 7:13-21
Griffths et al. (1993) EMBO J 12:725-734
Hawkins et al. (1992) J Mol Biol 226:889-896
Hirofumi Miyazono et al, Seikagaku, 61, 1023 (1939)
Hirofumi Miyazono et al., Seikagaku, 61, 1023 (1989)
Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137
J Exp Med. 1989 Jan 1; 169(1): 73-86
J Immunol. 1993 Mär 15;150(6):2305-15
Jones et al. 1986 Nature 321:552-525
K. Hiyama und S. Okada, J. Biochem. (Tokio), 80, 1201 (1976)
K. Hiyama und S. Okada, J. Biol. Chem., 250, 1824 (1975)
Kabat et al. (1991), „Sequences of Proteins of Immunological Interest", 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD („Kabat"-Nummerierungsschema), Al-Lazikani et al., (1997) JMB 273,927-948
Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917
Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242, und Chothia, C. et al. (1987) J.Mol. Biol. 196:901-917
Labrijn et al., PNAS 2013;110(13):5145-5150 und Labrijn et al. Nature Protocols 2014;9(10):2450-63
Li Hanchen et al. Tumor Microenvironment: The Role of the Tumor Stroma in Cancer. J of Cellular Biochemistry 101: 805-815 (2007)
Liu et al. (1987) PNAS 84:3439-3443
Liu et al., 1987, J. Immunol. 139:3521-3526
Lonberg, N. et al. 1994 Nature 368:856-859
Martens T et al. A novel one-armed antic-Met Antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12:6144-52; PMID:17062691
McConnell und Hoess, 1995, J Mol. Biol. 250:460
Moore GL et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 2011; 3:546-57; PMID: 22123055
Morrison et al., Europäische Patentanmeldung 173,494
Morrison, S. L., 1985, Science 229:1202-1207, von Oi et al., 1986, BioTechniques 4:214
Morrison, S.L. et al. 1994 Proc. Natl. Acad. Sei. USA 81:6851-6855
Nature. 2001 Feb 22;409(6823):1055-60 „Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells
Nishimura et al., 1987, Canc. Res. 47:999-1005
Oncoimmunology 2016; 5(1): e1052930
Pardoll. Nat. Rev. Cancer 12.4(2012):252-64
Proc Natl Acad Sei U S A. 24. Mai 2005; 102(21): 7641-7646
Rakoff-Nahoum S. & Medzhitov R., 2009. Toll-like receptors and cancer. Nat Revs Cancer 9:57-63
Ridgway, J. et al. (1996) Prot. Engineering 9(7): 617-621
Rosenberg et al., New Eng. J. of Med. 319: 1676, 1988
Saleh et al., Cancer Immunol. Immunother., 32:180-190 (1990)) und auch aufgrund möglicher allergischer Reaktionen (siehe z. B. LoBuglio et al., Hybridoma,5:5117 5123 (1986)
Shaw et al., 1988, J. Natl Cancer Inst. 80:1553-1559)
Speiss et al. Molecular Immunology 67 (2015) 95-106; und Klein et al mAbs 4:6, 653-663
Spiess C et al. (2015) Alternative molecular formats and therapeutic applications for bispecific antibodies. Molekulare Immunologie 67: 95-106
Sun et al. (1987) PNAS 84:214-218
T. Yamagata et al., J. Biol. Chem., 243, 1523 (1968)
T. Yamagata et al., J. Biol. Chem., 243, 1523 (1968), S. Suzuki et al., J Biol. Chem., 243, 1543 (1968)
Tramontano et al., 1994, J. Mol. Recognit. 7:9; und Martinet al., 1994, EMBO J. 13:5303-5309
Verhoeyan et al. 1988 Science 239:1534; Beidler et al. 1988 J. Immunol. 141:4053-4060
Viney et al., (Hybridoma. 1992 Dec;11 (6):701-13
Viney et al., (Hybridoma. 1992 Dec;11 (6):701-13)
Wang CY, et al., Int. J. Oncol. (2016) 48(6):2247-56
Wang CY, et al., Int. J. Oncol. (2016) 48(6):2247-56)
Wood et al. (1985) Nature 314:446-449
Yassai et al., (2009) Immunogenetics 61(7) S.:493-502; Wei S. und Concannon P. (1994) Human Immunology 41(3) S.: 201-206
YM Michelacci und CP Dietrich, Biochem. Biophys. Res. Commun., 56, 973 (1974), Y. M. Michelacci und C. P. Dietrich, Biochem. J., 151, 121 (1975), Kenichi Maeyama et al., Seikagaku, 57, 1189 (1985)

Also Published As

Publication number Publication date
JP2024170589A (ja) 2024-12-10
US20230034161A1 (en) 2023-02-02
US20220064297A1 (en) 2022-03-03
US20250215085A1 (en) 2025-07-03
US12286477B2 (en) 2025-04-29
JP2021530246A (ja) 2021-11-11
US20230031734A1 (en) 2023-02-02
US20230127740A1 (en) 2023-04-27
JP7554742B2 (ja) 2024-09-20
CN112955465A (zh) 2021-06-11
AU2019297451A1 (en) 2021-01-28
US20230174650A1 (en) 2023-06-08
US20250340640A1 (en) 2025-11-06
US20240076377A1 (en) 2024-03-07
US20240301060A1 (en) 2024-09-12
CA3105448A1 (en) 2020-01-09
US20210277119A1 (en) 2021-09-09
US11965025B2 (en) 2024-04-23
US20230142522A1 (en) 2023-05-11
US11845797B2 (en) 2023-12-19
WO2020010250A2 (en) 2020-01-09
US12351632B2 (en) 2025-07-08
EP3818083A2 (en) 2021-05-12
US20230025484A1 (en) 2023-01-26
US20230272074A1 (en) 2023-08-31
WO2020010250A3 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
US12286477B2 (en) Anti-TCR antibody molecules and uses thereof
US12486326B2 (en) Anti-TCR antibody molecules and uses thereof
US20210380670A1 (en) Multifunctional molecules that bind to calreticulin and uses thereof
US20250099579A1 (en) Multispecific molecules binding to tcr and uses thereof
US20240409636A1 (en) Multifunctional molecules binding to tcr and uses thereof
US20250297007A1 (en) Multifunctional molecules binding to tcr and uses thereof
US20240400990A1 (en) Immune cell populations and uses thereof
WO2021138407A2 (en) Multifunctional molecules that bind to cd33 and uses thereof
WO2024226532A2 (en) Multifunctional molecules binding to tcr and uses thereof
WO2025222063A2 (en) Multifunctional molecules binding to tcr and uses thereof

Legal Events

Date Code Title Description
R207 Utility model specification
R150 Utility model maintained after payment of first maintenance fee after three years
R151 Utility model maintained after payment of second maintenance fee after six years